Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
Incidence of psychotic experiences peaks during late adolescence, suggests a recent study, which also highlights an unmet need for care in young people with psychotic disorders.
Continuous subcutaneous insulin infusion (CSII) appears to be superior to multiple daily injections (MDI) for the management of type 1 or 2 diabetes, leading to lower rates of cardiovascular events and better glycaemic control, according to a new study.
The anticonvulsant drugs levetiracetam, fosphenytoin and valproate all demonstrate efficacy for benzodiazepine-refractory convulsive status epilepticus, with each drug inducing seizure cessation and improving alertness in most patients and yielding similar safety outcomes, according to data from the Established Status Epilepticus Treatment Trial (ESETT).
Patients with chronic hepatitis B (CHB) virus infection who are HBeAg-negative are more likely to have advanced liver fibrosis than those with a positive HBeAg status, a study has found.
In elderly adults with myelodysplastic syndrome (MDS), the comprehensive geriatric assessment can detect geriatric-related health issues and may be useful in identifying those unlikely to benefit from azacytidine treatment, a recent study has shown.
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.
Special Reports
In collaboration with the Malaysian Society of Infectious Diseases and Chemotherapy,Sanofi Pasteur Malaysia commemorated the launch of VaxigripTetra® by inviting three distinguished speakers to provide valuable insights into the prevalence of influenza and how vaccination can truly impact the health status of patients in general.
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
At a recent Pfizer-sponsored symposium, held in conjunction with the 17th Urological Association of Asia Congress at Kuala Lumpur Convention Centre, Professor Bannakij Lojanapiwat gave a lecture on the pathophysiology and management of overactive bladder (OAB) and lower urinary tract symptoms (LUTS), highlighting the importance of individualised pharmacological intervention in optimizing patient outcomes.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.
At a Duopharma-sponsored symposium during the Diabetes Asia Conference 2019 at Hotel Istana, Kuala Lumpur, Professor Dato’ Dr Mafauzy Mohamed spoke about the role of biosimilar insulin glargine in improving access to diabetes treatment, presenting important evidence that affirms the quality, efficacy and safety of the biosimilar product.
Conference Reports
Children with inflammatory bowel disease (IBD) were more likely to use psychotropic medications than those without the disease, according to a study presented at AIBD 2019 Conference.
The adalimumab biosimilar BI 695501 shows similar efficacy and safety profile as its reference product in patients with moderate-to-severe Crohn's disease (CD), according to a phase III study recently presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Conference.
The reduced incidence of breast cancer with 5-year prophylaxis with the aromatase inhibitor anastrozole among women at high risk of the disease persists even after anastrozole cessation, suggests long-term results of the IBIS-II* trial presented at SABCS 2019.
The addition of tucatinib to a trastuzumab-capecitabine regimen improved progression-free survival (PFS) in patients with HER2+ metastatic breast cancer (MBC) previously treated with multiple HER2-targeted agents, according to the HER2CLIMB* study presented at SABCS** 2019. Additionally, this improved PFS was also noted in patients with brain metastases.
Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.
A left ventricular ejection fraction (LVEF) cut-off of 60 percent may identify patients with heart failure (HF) with mid-range or preserved ejection fraction (mrEF or pEF) who could benefit from drug therapy.
The combination of venetoclax with bortezomib and dexamethasone (Bd) significantly improves response rates in patients with relapsed/refractory multiple myeloma (RRMM), although survival, according to updated results of the BELLINI* study presented at ASH 2019.
Multimedia
